Items Tagged ‘Aggressive/Intermediate Grade Non-Hodgkin’s Lymphoma’

June 20th, 2016

CAR Therapy Effective in Advanced Lymphoma

By

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types of lymphomas. This type of treatment is continuing to produce impressive results, and is demonstrating effectiveness in several different types […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, asco, CAR, CAR T, chimeric antigen receptor, Follicular Lymphoma, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Leukemia, Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma


December 17th, 2014

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment

By

HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection and poor graft function due to their need for HIV medications. Results from the clinical trial, presented at the American Society of Hematology […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Follicular Lymphoma, General HIV Related Cancers, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, hiv, hiv cancer, HIV Related Cancers, Indolent/Low Grade Non-Hodgkin's Lymphoma, Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, nhl


September 4th, 2014

Adding Revlimid to R-CHOP May Improve Outomes of Selected Patients with NHL

By

The results of a recently completed study reported in the Journal of Clinical Oncology indicate that the addition of Revlimid® (lenalidomide) to R-CHOP the standard treatment for non hodgkin lymphoma (NHL) can overcome the negative prognostic effect of the non–germinal B-cell phenotype in diffuse large B-cell lymphoma which is associated with significantly worse outcomes with […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, Lymphoma, News, nhl, Non-Hodgkin's Lymphoma, Recurrent Non-Hodgkin's Lymphoma, revlimid


September 3rd, 2014

Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Reported to be Effective in Aggressive Non-Hodgkin’s Lymphoma at the National Cancer Institute (NCI)

By

SANTA MONICA, Calif., Aug. 25, 2014 (GLOBE NEWSWIRE) — Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, announced the publication of clinical results in a cohort of patients demonstrating the potential to treat aggressive non-Hodgkin’s lymphoma with an anti-CD19 chimeric […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, anti-CD19, dlbcl, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, News, nhl, Non-Hodgkin's Lymphoma, Recurrent Non-Hodgkin's Lymphoma, T cell therapy


May 28th, 2014

Lenalidomide Added to R-CHOP21 Therapy Shows High Response in Elderly, Untreated Large B-Cell Lymphoma Patients

By

Researchers reported in the journal The Lancet Oncology that the addition of lenalidomide to the standard R-CHOP21 regimen elicited a high response rate in elderly patients with untreated diffuse large B-cell lymphoma. In addition, the combination therapy was deemed to be safe in this population. Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, b-cell lymphoma, dlbcl, Follicular Lymphoma, Lymphoma, News, nhl, Non-Hodgkin's Lymphoma


September 4th, 2013

Celiac Disease Associated with Higher Risk of Lymphoma

By

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published in the Annals of Internal Medicine.[1] Celiac disease is an autoimmune disorder of the small intestine characterized by intolerance to gluten, which is a […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Follicular Lymphoma, Health and Wellness, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, Indolent/Low Grade Non-Hodgkin's Lymphoma, Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma, Recurrent Non-Hodgkin's Lymphoma, Screening/Prevention Non-Hodgkin's Lymphoma, T-Cell Non-Hodgkin's Lymphoma


June 25th, 2013

Routine CT Scans May Not Be Necessary for Many Lymphoma Survivors

By

After treatment for diffuse large B cell lymphoma (DLBCL), only a small minority of patients have a relapse detected through routine surveillance CT scans alone, suggesting that routine scans have limited value for these patients. These results were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO). DLBCL is the […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma


May 31st, 2013

Rituxan May Prevent Need for Radiation in Mediastinal B-Cell Lymphoma

By

A dose-adjusted, infusion approach to aggressive chemotherapy with Rituxan® (rituximab) may allow patients with primary mediastinal B-cell lymphoma to skip radiation, according to the results of a study published in the New England Journal of Medicine. Non-Hodgkin’s lymphoma (NHL) refers to a group of cancers that originate in different cells of the immune system. Diffuse large […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma


April 5th, 2013

RIT Conditioning with Zevalin Prior to Autologous Transplantation Improves Overall Survival in Patients with DLCL

By

Radioimmunotherapy conditioning with Zevalin® (ibritumomab tiuxetan) prior to autologous stem cell transplantation in patients with diffuse large cell lymphoma offers a similar relapse incidence to total body irradiation, but has lower toxicity and improved overall survival, according to the results of a study published in Biol Blood Marrow Transplant. Non-Hodgkin’s lymphoma (NHL) refers to a group […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma


April 2nd, 2013

Treanda Plus Rituxan is Not Inferior to R-CHOP and R-CVP for advanced NHL

By

The combination of Treanda® (bendamustine) and Rituxan® (rituximab) was found to be noninferior to the commonly used chemotherapy regimens R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) and R-CVP (rituximab plus cyclophosphamide, vincristine, and prednisone) in patients with previously untreated advanced indolent non-Hodgkin’s lymphoma (NHL) or mantle cell lymphoma (MCL), according to the results of […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma


March 29th, 2013

Zevalin Plus Nonmyeloablative Allogeneic Transplantation Effective in High-Risk B-Cell NHL

By

The addition of Zevalin® (ibritumomab tiuxetan) to nonmyeloablative allogeneic transplantation (NMAT) is safe and produces early responses and prolonged disease control in high-risk patients with B-cell non-Hodgkin’s lymphoma, according to the results of a study published in Blood. Non-Hodgkin’s lymphoma (NHL) is a form of cancer that begins in the cells of the lymph system. […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma


March 22nd, 2013

Zevalin Plus BEAM Chemotherapy Superior to BEAM Alone in Aggressive Lymphoma

By

Standard-dose Zevalin® (ibritumomab tiuxetan) combined with BEAM high-dose chemotherapy is safe and possibly more effective than BEAM therapy alone as a conditioning regimen for autologous stem cell transplantation (ASCT), according to the results of a study published in Cancer. High-dose chemotherapy plus autologous stem cell transplantation (ASCT) is standard therapy for refractory/relapsed aggressive lymphoma; however, […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Autologous Stem Cell Transplant, Lymphoma, News, Non-Hodgkin's Lymphoma, Stem Cell Transplant


March 1st, 2013

Dose-Dense R-CHOP plus Zevalin Improves Response in Diffuse Large B-Cell Lymphoma

By

Dose-dense R-CHOP followed by Zevalin® (ibritumomab tiuxetan) converts partial responses to complete responses and maintains durable responses in patients with untreated diffuse large B-cell lymphoma, according to the results of a study presented at the 52nd annual meeting of the American Society of Hematology (ASH) in Orlando, Florida. Non-Hodgkin’s lymphoma (NHL) refers to a group of […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma


February 22nd, 2013

Sequential R-CHOP plus Zevalin Shows Promise in High-Risk Elderly Patients with Diffuse Large B-Cell Lymphoma

By

Sequential R-CHOP followed by Zevalin® (ibritumomab tiuxetan) produces encouraging outcomes in high-risk elderly patients with diffuse large B-cell lymphoma, according to the results of a study presented at the 52nd annual meeting of the American Society of Hematology (ASH) in Orlando, Florida. Non-Hodgkin’s lymphoma (NHL) refers to a group of cancers that originate in different cells […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma


February 15th, 2013

Zevalin Safe and Effective in High-Risk Elderly Patients with Diffuse Large B-Cell Lymphoma

By

Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is safe and effective in high-risk elderly patients with diffuse large B-cell lymphoma, according to the results of a study published in Clinical Cancer Research Non-Hodgkin’s lymphoma (NHL) refers to a group of cancers that originate in different cells of the immune system. Diffuse large B-cell NHL is a […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma